Neurocrine Biosciences, Inc. (NBIX) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Neurocrine Biosciences, Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| P/E Ratio | 29.49x | 40.15x | 51.55x | 74.06x | 89.92x | 21.91x |
| P/B Ratio | 4.34x | 5.29x | 5.77x | 6.70x | 5.86x | 7.92x |
| P/S Ratio | 4.93x | 5.82x | 6.82x | 7.69x | 7.11x | 8.53x |
| Profitability | ||||||
| Gross Margin | 98.2% | 98.6% | 97.9% | 98.4% | 98.7% | 99.0% |
| Operating Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% |
| Net Margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% |
| EBITDA Margin | 23.3% | 27.2% | 22.0% | 17.8% | 12.2% | 14.2% |
| Liquidity | ||||||
| Current Ratio | 3.39x | 3.40x | 2.45x | 2.70x | 3.96x | 5.45x |
| Quick Ratio | 3.30x | 3.28x | 2.40x | 2.64x | 3.83x | 5.30x |
| Leverage | ||||||
| Debt/Equity | 0.13x | 0.18x | 0.19x | 0.15x | 0.32x | 0.37x |
YoY = year-over-year change. Source: FMP..